EXCLUSIVE LICENSE AGREEMENT
Between BioTime, Inc. and ▇▇▇▇▇▇ Laboratories
TABLE OF CONTENTS
1. DEFINITIONS................................................................2
2. LICENSE GRANT.............................................................5
3. LICENSE FEES..............................................................6
4. ROYALTIES.................................................................7
5. ROYALTY AND LICENSE PAYMENTS..............................................7
6. PRODUCT PROMOTIONAL ACTIVITIES...........................................11
7. CLINICAL TRIALS AND REGULATORY APPROVAL - PRODUCT AND IMPROVED PRODUCT...11
9. PATENT AND TRADEMARK MARKING.............................................14
10. STANDBY CONTRACT MANUFACTURING AGREEMENT................................15
11. RIGHT OF FIRST REFUSAL - NEW PRODUCTS...................................15
12. INFRINGEMENT AND INDEMNIFICATION........................................19
13. CONFIDENTIALITY.........................................................22
14. TERM AND TERMINATION....................................................22
15. REPRESENTATIONS AND WARRANTIES OF LICENSOR..............................23
16. REPRESENTATIONS AND WARRANTIES OF ABBOTT................................24
17. NOTICES.................................................................25
18. ALTERNATIVE DISPUTE RESOLUTION..........................................25
19. PUBLICITY...............................................................25
20. APPLICABLE LAW..........................................................26
21. ASSIGNMENT..............................................................26
22. ENTIRE AGREEMENT........................................................26
23. SEVERABILITY............................................................26
24. CUMULATIVE RIGHTS AND REMEDIES..........................................27
25. WAIVER - MODIFICATION OF AGREEMENT......................................27
EXHIBIT A HEXTEND(R) FORMULATION............................................28
1
EXHIBIT B PATENT RIGHTS.....................................................29
EXHIBIT C MILESTONE PAYMENTS AND SALES RELATED LICENSE FEES.................30
EXHIBIT C.1 COMPOSITION OF MATTER, MINIMUM CLAIMS............................32
EXHIBIT D ROYALTIES.........................................................33
EXHIBIT D.1 CALCULATION OF LICENSE FEE AND ROYALTY PAYMENTS.................34
EXHIBIT E NO VOLUME LIMITATION..............................................35
EXHIBIT F PRODUCT STANDBY CONTRACT MANUFACTURING AGREEMENT..................36
EXHIBIT G ALTERNATIVE DISPUTE RESOLUTION....................................38
EXHIBIT H PRODUCT PROMOTIONAL ACTIVITIES....................................42
2
EXCLUSIVE LICENSE AGREEMENT
This Agreement is made this 23rd day of April, 1997 by and
between BioTime, Inc., ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
("Licensor") and ▇▇▇▇▇▇ Laboratories, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇,
▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇ ("Abbott").
Premises
This agreement defines the terms to which Abbott and Licensor agree, in order to
commercialize Hextend(R) intravenous solution, which has been developed by
Licensor. The process by which Abbott and Licensor may commercialize other
products currently under development by Licensor, or which Licensor may develop
in the future having utility in the areas of plasma volume expansion, organ
preservation, blood replacement, and low temperature surgery, is also defined.
1. Definitions
Where used in this Agreement the following terms shall have the
meanings ascribed below:
(a) "Affiliate" means any entity, except Abbott, in which Abbott owns,
directly or indirectly, not less than fifty percent (50%) of such entity's
assets or voting securities.
(b) "Confidential Information" means any information including, but not
limited to, ideas, proposals, plans, Know-How, reports, drawings, designs, data,
discoveries, inventions, improvements, suggestions, specifications, products,
samples, components and materials relating to the Product and all information
relating to the manufacture, formulation, analysis, stability, pharmacology,
toxicology, pathology, clinical data, results of clinical efficacy studies,
clinical effects and indications for use of the Product which a party discloses
to the other party except any portion thereof which:
(i) is known to the receiving party at the time of disclosure
and documented by written records made prior to the date of
this Agreement;
(ii) is disclosed to the receiving party by a Third Person who
has a right to make such disclosure;
(iii) becomes patented, published or otherwise part of the public
domain as a result of acts by a Third Person through no
fault of the receiving party or an Affiliate or sublicensee
of the receiving party; or
(iv) is independently developed by the receiving party without
the use of Confidential Information, as evidenced by its
written records.
3
(c) "Effective Date" means the date of this Agreement.
(d) "Exclusive License" means a license whereby ▇▇▇▇▇▇'▇ rights shall
be sole and exclusive and shall operate to exclude all others, including
Licensor.
(e) "FDA" means the United States Food and Drug Administration or any
successor entity thereto.
(f) "FDA Application" means any investigational new drug application,
new drug application, supplemental new drug application, abbreviated new drug
application, investigational device exemption, premarket approval application,
510-K application, any other application required by the FDA to test, use,
market, or distribute a pharmaceutical or biological product for human use, and
any amendment to any of the foregoing.
(g) "High Molecular Weight Hetastarch" means hydroxyethyl starch, an
artificial colloid derived from a waxy starch composed almost entirely of
amylopectin, with hydroxyethyl ether groups introduced into the glucose units of
the starch. The resultant material is hydrolyzed to yield a product suitable for
the intended use. Molar substitution of hydroxyethyl ether groups is 0.7,
meaning that there are 7 hydroxyethyl groups for every 10 glucose units. The
average molecular weight of the resultant material is greater than 400,000.
(h) "Improved Product" means any and all new developments or versions
of the Product made by Licensor, including, but not be limited to, new
therapeutic indications for Normothermic Use, and developments intended to
enhance the safety and efficacy of the Product in Normothermic Use.
(i) "Know-How" means that proprietary technology developed by Licensor
for manufacturing or formulating the Product, including, but not limited to:
manufacturing data; formulation or production technology; methods of synthesis,
isolation and purification methods and other manufacturing information required
to manufacture the Product; and that proprietary data developed by Licensor
related to pharmacology, toxicology, pathology, clinical data, results of
clinical efficacy studies, clinical effects and indications for use of the
Product in Normothermic Use.
(j) "Licensed Patents" means: (i) the patents and patent applications
listed in Exhibit B hereto; (ii) any patent or patent application hereafter
acquired by Licensor and any patent or patent application under which Licensor
becomes licensed and with the right to sublicense Abbott, during the term of
this Agreement regarding the Product, its manufacture, use or sale, including
methods of use and screening or processes that use the Product; (iii) all
patents arising from applications identified in (i) or (ii) and any divisions,
continuations and continuations-in-part defined in (i) or (ii); (iv) any
extension, renewal or reissue of a patent identified in (i), (ii) or (iii); and
4
(v) any continuation or divisional of any licensed patent application and any
reissue or reexamination of any patent identified in (i) through (iv); but only
to the extent that the patents identified in (i) through (v) pertain to
Normothermic Use of the Product. Licensor shall promptly notify Abbott of any
such patent or patent application hereafter acquired by Licensor and any patent
or patent application under which Licensor becomes licensed and with the right
to sublicense Abbott, and such patent or patent application shall be added to
Exhibit B.
(k) "Licensed Trademark" means Hextend(R) and any other trademark
developed or acquired by Licensor for use in connection with the sale of the
Product in the Territory.
(l) "NDA" means a new drug application submitted to the FDA.
(m) "Net Sales" means the gross sales of the Product (including any and
all Improved Products) billed to customers by Abbott or its Affiliates or
sublicensees in the applicable period, less: (i) the allowances and adjustments
separately and actually credited or payable to customers for spoiled, damaged,
outdated and returned Product, whether during the specific royalty period or
not; (ii) trade discounts earned or granted; (iii) cash discounts allowed or
allowable; (iv) transportation charges, handling charges, sales taxes, excise
taxes and duties, and other similar charges incurred by Abbott to the extent
such charges pertain to the Product; (v) rebates and Group Purchasing
Organization administrative fees granted, if any; and (vi) the cost of the High
Molecular Weight Hetastarch used in the manufacture of the Product or Improved
Product for sales made after all Licensed Patents have expired and a Third
Person receives a Notice of Approvability or equivalent from the appropriate
regulatory authority, or otherwise lawfully markets a generic version of the
Product or Improved Product, provided that the deduction shall apply only to
sales of the Product or Improved Product equivalent to the generic equivalent
receiving Notice of Approvability or otherwise lawfully being marketed, on a
country by country basis. In the case of (ii), (iii) and (v), such discounts,
rebates and fees shall be deducted from gross sales only to the extent actually
granted to customers, and only to the extent granted with respect to the Product
during the applicable period.
(n) "New Product" means any product other than the Product or an
Improved Product.
(o) "Normothermic Use" means use of the Product in surgical or
therapeutic procedures in which the patient's body temperature is 12 degrees
Centigrade or higher.
(p) "Product" means the pharmaceutical product generally described in
Exhibit A and presently known under the trademark Hextend,(R) and any and all
Improved Products covered by the Licensed Patents, which use only High Molecular
Weight Hetastarch as an oncotic agent and have pharmacologic profiles and
therapeutic indications normally considered medically equivalent.
(q) "Proprietary Rights" means all of Licensor's intellectual property
rights (except Licensed Patents and Licensed Trademarks) and interests in, to,
5
or covering the Product, or the manufacture or use of the Product, to the extent
that such property rights and interests are of such legal status and nature as
to permit the same to be lawfully licensed and, without limiting the generality
thereof, specifically include unpatented inventions, ideas, data, Know-How,
technology, trade secrets and Confidential Information; but only to the extent
that the foregoing pertain to the Use of the Product within License granted.
(r) "Territory" means the United States, its territories and
possessions (including Puerto Rico), and Canada.
(s) "Third Person" means any natural person, corporation, partnership,
limited partnership, limited liability company, trust, association or other
entity other than Abbott, an Affiliate, or Licensor.
(t) "Total Body Washout" is the process of totally removing a patient's
blood, where hematocrit drops to 5% or below.
(u) "Valid Claim" means any claim of an issued and unexpired patent
which (i) has not been held unenforceable, unpatentable, or invalid by a
decision of a court or governmental agency of competent jurisdiction in the
Territory, unappealable or unappealed within the time allowed for appeal, and
(ii) Licensor has not admitted to be invalid or unenforceable through reissue,
disclaimer or otherwise.
2. License Grant
(a) Licensor hereby grants to Abbott an Exclusive License in the
Territory to make, have made, use, sell, offer to sell and import the Product in
packaging containing two liters of Product (net contents) or less (including any
and all Improved Products) under Licensed Patents, Licensed Trademarks, and
Proprietary Rights for Normothermic Use other than Total Body Washout, with the
right to grant sublicenses to Affiliates and Third Persons. Such license shall
be irrevocable, except as hereinafter expressly provided.
(b) Abbott agrees not to use or permit any Affiliate or sublicensee to
use any Licensed Patents, Licensed Trademarks, and Proprietary Rights for any
use other than the manufacture and sale of the Product for the use described in
paragraph (a) of this Article in the Territory. Abbott will not sell, have sold,
or permit any Affiliate or sublicensee to sell or have sold the Product outside
the Territory or for uses other than the use described in paragraph (a) of this
Article in the Territory. If any Product is sold (by or on behalf of Abbott, any
of its Affiliates or sublicensees) to a Third Person that intends to resell the
Product, Abbott will require such Third Person to agree not to resell the
Product outside the Territory. If Abbott or any of its Affiliates or
sublicensees becomes informed of a violation of that agreement by the Third
Person, Abbott will notify Licensor of such violation, and Abbott will take
reasonable means to enforce the Third Person's agreement, including, without
limitation, by discontinuing sales to such Third Person; provided however,
Abbott shall not be required to file lawsuits against Third Persons to enforce
such agreements.
6
(c) Licensor retains (i) the right under Licensed Patents, Proprietary
Rights, Licensed Trademarks, and to the Product for research, development and
clinical testing of New Products, technology, Improved Products, and additional
therapeutic indications of the Product inside and outside the Territory; (ii)
all rights to Licensed Patents, Proprietary Rights, Licensed Trademarks, and the
Product for any purpose outside the Territory, including but not limited to the
right to sell, assign, transfer and license to Third Parties, and the right to
make, have made, use, and sell the Product outside the Territory; and (iii) all
rights to Licensed Patents, Proprietary Rights, Licensed Trademarks, and the
Product, including but not limited to the right to make, have made, use, and
sell the Product, inside the Territory for Total Body Washout and uses other
than Normothermic Use, and the right to sell, assign, transfer and license such
rights to Third Parties. If any Product is sold (by or on behalf of Licensor,
any of its affiliates or sublicensees) to a Third Person that intends to resell
the Product, Licensor will require such Third Person to agree not to resell the
Product inside the Territory for use in any application covered by ▇▇▇▇▇▇'▇
Exclusive License. If Licensor or any of its affiliates or sublicensees becomes
informed of a violation of that agreement by the Third Person, Licensor will
notify Abbott of such violation, and Licensor will take reasonable means to
enforce the Third Person's agreement, including, without limitation, by
discontinuing sales to such Third Person; provided however, Licensor shall not
be required to file lawsuits against Third Persons to enforce such agreements.
3. License Fees
In partial consideration for the license granted to Abbott hereunder,
Abbott agrees to pay Licensor license fees up to an aggregate amount of
$40,000,000 as follows:
(a) Milestone payments, up to an aggregate amount of $2,500,000, as
provided in Exhibit C; and
(b) License fees of up to $37,500,000 based upon Net Sales in the
Territory, as provided in Exhibit C; provided that ▇▇▇▇▇▇'▇ obligation to pay
such license fees based upon Net Sales shall terminate on a product by product
and country by country basis, after all Licensed Patents (other than Licensed
Patents that contain no Valid Claims covering the Product or an Improved Product
or use thereof) have expired, or upon a Third Person obtaining a "Notice of
Approvability" or equivalent, or otherwise commencing lawful marketing, within
that country, of a generic equivalent to the Product or Improved Product being
marketed by Abbott.
4. Royalties
(a) Abbott agrees to pay to Licensor royalties based upon Net Sales of
the Product or Improved Product in the Territory, as provided in Exhibit D;
provided that ▇▇▇▇▇▇'▇ obligation to pay such royalties based upon Net Sales
shall terminate on a product by product and country by country basis, after all
Licensed Patents (other than Licensed Patents that contain no Valid Claims
7
covering the Product or an Improved Product or use thereof) have expired, and
upon a Third Person obtaining a "Notice of Approvability" or equivalent, or
otherwise commencing lawful marketing, within that country, of a generic
equivalent to the Product or Improved Product being marketed by Abbott.
(b) All sales of the Product by Abbott or any Affiliate or sublicensee
shall be documented.
5. Royalty and License Payments
(a) Royalty and License Payment Report. Each royalty payment shall be
accompanied by a statement which sets forth the following information as to each
Product: the quantity of Product sold by list number; the gross sales price; the
description and amount of each cost, charge, expense or other amount deducted
from the gross sales price to compute Net Sales; the Net Sales in each country
of the Territory; and the exchange rate used to convert foreign currency into
U.S. dollars. All currency amounts shall be expressed in United States dollars.
(b) Royalty and License Payments -- Annualized Net Sales. Payments
shall be made in United States dollars within ninety (90) days after the last
day of March, June, September and December for royalties and license fees
accruing on annualized Net Sales during the three (3) preceding calendar months.
Payment amounts for each three month period will be determined by subtracting
payments made in previous calendar quarters of the year from the amount due on
Net Sales for all completed calendar quarters in the year. The procedure used to
calculate payments is more fully described in Exhibit D.1. Royalties and license
fees shall be determined separately, and prior or excess payments on account of
one shall not be charged or credited against the other, except for excess
license fees associated with Net Sales in the fourth quarter of 2006.
(c) Exchange Rates. All payments of royalties and license fees shall be
computed in United States dollars at the exchange rate prevailing in each
country in the Territory at the close of the last business day of the third week
next preceding the date on which royalties or license fees are payable. The
exchange rates used for such conversion shall be those set forth in the Wall
Street Journal, Midwest Edition.
(d) Royalty and License Fee Payments - Place. Payments due Licensor
under this Agreement shall be made by wire transfer to an account of Licensor at
a bank located in the United States designated from time to time in writing by
Licensor.
(e) No Multiple Royalties. No multiple royalties shall be payable on
the basis that the manufacture, use or sale of a Product is or becomes covered
by more than one Valid Claim of a Licensed Patent or more than one Licensed
Patent.
(f) No Royalties Payable Between Affiliates. No royalties shall be
payable on Net Sales among Abbott, its Affiliates or sublicensees or between
Affiliates and sublicensees, provided that Abbott, its Affiliates and
sublicensees resell to Third Persons the quantities of the Product in question.
8
(g) Records and Audit. Abbott, its Affiliates and sublicensees shall
keep and maintain records of sales made pursuant to the Exclusive License
granted hereunder. Such records shall be open to inspection at any reasonable
time within three (3) years after the royalty period to which such records
relate by a nationally recognized independent certified public accountant
selected by Licensor, approved by Abbott, which approval shall not be
unreasonably withheld, and retained at Licensor's expense. Said accountant shall
sign a confidentiality agreement prepared by Abbott (which shall not prohibit
disclosure of information in any Alternative Dispute Resolution (ADR) proceeding
between the parties) and shall then have the right to examine the records kept
pursuant to this Agreement and report the findings of said examination of
records to Licensor as is necessary to (i) evidence that records were or were
not maintained and used in accordance with this Agreement, and (ii) report any
impropriety or inaccuracy in the determination or payment of any amount due to
be paid under this Agreement. A copy of any report provided to Licensor by the
independent certified public accountant shall be given concurrently to Abbott.
Any underpayments by Abbott to Licensor discovered by such an audit shall be
repaid with interest, at rates then prevailing for comparable commercial loans.
Overpayments by Abbott may be credited against future payments due Licensor.
(h) Payment by Affiliate. Licensor agrees that any sublicensee or
Affiliate of Abbott may pay, on behalf of Abbott, any obligation of Abbott under
this Agreement and that such payment, when received, shall be deemed received in
lieu of payment by Abbott in satisfaction of such obligation under this
Agreement. Said sublicensee or Affiliate shall make payment to Licensor in
United States dollars at a bank account designated by Licensor. The royalty
payment shall be converted from foreign currency to United States dollars using
exchange rates and conversion dates stated in Article 5(c) above. Said
sublicensee or Affiliate shall use its best efforts to convert the royalties
payable on sales in any country to United States dollars; provided, however,
that if conversion to and transfer of United States dollars cannot be made in
any country for any reason, payment of royalties may be made in the currency of
the country in which such sales are made, and deposited in an account in
Licensor's name in a bank designated by Licensor in any such country.
(i) Agreement to Contract with Affiliate or Sublicensee. Upon written
request of Abbott, Licensor will contract directly with any Affiliate or
sublicensee of Abbott to provide to said Affiliate or sublicensee the right and
license granted hereunder in any of the Territory on substantially the same
terms and conditions as those contained in this Agreement; provided that Abbott
shall guarantee to Licensor full performance of such Affiliate's or
sublicensee's duties and obligations under such contract. Any direct or indirect
expenses borne by Licensor in such re-contracting will be reimbursed promptly by
Abbott.
(j) Royalty License Restrictions and Maximum Payments. If any country
restricts the royalty rate or amount payable on account of sales of Product in
such country, the amount payable hereunder shall not exceed the maximum amount
payable under applicable laws, regulations or administrative rulings of such
country.
9
(k) Taxes. All taxes assessed or imposed against, or required to be
withheld from royalty or license payments due Licensor shall be deducted from
amounts payable under this Agreement and shall be paid to appropriate fiscal or
tax authorities on behalf of Licensor. Abbott shall promptly forward any
receipts or other documents received by Abbott, its Affiliates and sublicensees
evidencing payment of such taxes to Licensor.
(l) Loan. Within thirty (30) days after the first sale of the Product
by Abbott or any Affiliate or sublicensee, Abbott shall make an interest free
loan to Licensor in an amount equal to one-quarter of the payments projected to
be due for the first year of Product sales, as reflected in ▇▇▇▇▇▇'▇ marketing
plans and sales projections, a copy of which shall be given to Licensor. Such
loan shall be evidenced by a promissory note in form acceptable to and executed
by Licensor, which promissory note shall be due and payable thirty (30) months
after the date it is made, or within ninety (90) days after discontinuation of
▇▇▇▇▇▇'▇ Exclusive License for the Product, whichever occurs first. The amount
due Abbott may be deducted from payments due Licensor by Abbott, at ▇▇▇▇▇▇'▇
option.
(m) Cannibalization of Abbott Product Sales by other Licensor Products.
In the event that Licensor licenses a product to a Third Person, or sells a
product in the Territory that can be medically substituted for Product licensed
to Abbott by Licensor, in packaging containing more than two liters (net of
overfill) of product, and unless Licensor can demonstrate that the net price per
liter range for substitutable product is not less than the net price per liter
range for Abbott Product, then:
(i) If Abbott demonstrates that its marketing efforts have not
decreased, any reduction in Abbott sales (losses) of Product
subsequent to introduction of said medically substitutable
product will be assumed to be the result of cannibalization of
Abbott Product sales.
(ii) Licensor will reimburse Abbott for its losses due to
cannibalization, up to 50% of any royalty and license payments
due Licensor for the quarter in which Abbott losses occurred.
(iii) All Abbott minimum Product sales will be eliminated.
(iv) If losses continue for more than two quarters, Licensor will
return 50% of the total milestone payments previously made by
Abbott, within 90 days of the end of the second quarter.
10
6. Product Promotional Activities
Abbott agrees to use the extensive sales, marketing and distribution
programs and facilities of its Hospital Products Division to promote, market,
distribute and sell the Product in the Territory in a manner similar to that
used by ▇▇▇▇▇▇ Hospital Products Division for comparable products, and at prices
and on other terms of sale reasonably expected to maximize Net Sales. Abbott
agrees to seek input from Licensor in defining a marketing program for the
Product; Abbott shall retain decision making power and management of the
marketing process. In addition, Abbott and Licensor contemplate that they will
engage in the activities described in Exhibit H in connection with the marketing
and development of the Product and Improved Products; provided that the
financial and budgetary parameters specified in Exhibit H are expressions of
intent only and neither party shall be deemed to have materially breached this
Agreement solely by virtue of failing to expend any such amount of funds in the
manner or time described in such Exhibit.
7. Clinical Trials and Regulatory Approval - Product and Improved Product
(a) Licensor is, at the date of this Agreement, conducting a Phase III
clinical trial of the Product (the "Phase III Trial") using High Molecular
Weight Hetastarch and Product manufactured by ▇▇▇▇▇, Inc. Abbott and Licensor
desire to include Abbott manufactured Product in the Phase III Trial at the
earliest date practicable. In order to accomplish this objective, Abbott will,
at ▇▇▇▇▇▇'▇ sole cost and expense do all of the following (i) Abbott will
manufacture and deliver to Licensor Product labeled, packaged, and manufactured
under conditions suitable and in quantities needed for use in the ongoing Phase
III Trial, (ii) provide Licensor with access to ▇▇▇▇▇▇'▇ drug master file and
such other documentation and information pertaining to the Product as may be
required to prepare or support any and all FDA Applications in connection with
the actual or proposed use of Abbott manufactured Product in the Phase III
Trial; (iii) perform and provide Licensor with the results of such stability
tests and other analysis as may be required to include Abbott manufactured
Product in the Phase III Trial; (iv) consent in writing to the use or
cross-referencing of ▇▇▇▇▇▇'▇ drug master file for High Molecular Weight
Hetastarch in connection with all FDA Applications in connection with the actual
or proposed use of Abbott manufactured Product in the Phase III Trial and in the
commercial manufacture, sale and distribution of the Product; and (v) cooperate
in all commercially reasonable respects with Licensor's efforts to prepare, file
and obtain approval of all FDA Applications for Abbott manufactured Product at
the earliest date practicable. All information provided Licensor by Abbott shall
be deemed ▇▇▇▇▇▇'▇ Confidential Information, and shall be used solely for the
purpose of obtaining FDA approval for Abbott manufactured Product under the
Exclusive License.
(b) Licensor agrees to use commercially reasonable efforts to obtain
any FDA approval or permission as may be required to include the Abbott
manufactured Product in the Phase III Trial. Licensor agrees to disclose to
Abbott the results of the Phase III Trial and the data gathered in the course of
the Phase III Trial, which results and data shall be deemed Licensor's
Confidential Information.
11
(c) If from time to time and at any time during the term of this
Agreement, Abbott and Licensor desire to commence a new clinical trial of the
Product or any Improved Product, Abbott will, at ▇▇▇▇▇▇'▇ sole cost and expense,
provide the services, information and Product for such new clinical trial
(regardless of phase) as provided in clauses (i) through (v) of paragraph (a) of
this Article with respect to the Phase III Trial. Licensor agrees to disclose to
Abbott the results of such clinical trials and the data gathered in the course
of such clinical trials, which results and data shall be deemed Licensor's
Confidential Information.
(d) Licensor agrees to consult with ▇▇▇▇▇▇ regarding the process of
obtaining regulatory approval for all Product or Improved Product in the
Territory, and permit ▇▇▇▇▇▇ to review and comment on submission content and
regulatory strategy. Licensor shall retain management of the regulatory process
and decision making power and shall retain the right to designate its own
personnel and consultants to manage and direct such regulatory process. All
regulatory approvals throughout the Territory and every improvement thereon will
be in the name of and owned by Licensor.
(e) In the event that Licensor is unable for any reason to complete its
responsibilities in obtaining regulatory approval for commercial sale of ▇▇▇▇▇▇
manufactured Product or Improved Product in a reasonably timely manner, ▇▇▇▇▇▇
in its reasonable judgment may by written notice to Licensor assume
responsibility for conducting such activities. Licensor will cooperate with
▇▇▇▇▇▇ in providing required access to all individuals, information, documents,
and other materials as needed to expeditiously obtain approval and market
Product or Improved Product. Licensor will execute any documents required to
expeditiously obtain approval for and market Product or Improved Product. ▇▇▇▇▇▇
may deduct its costs incurred in conducting these activities from any future
payments due Licensor by ▇▇▇▇▇▇, with interest charged at rates then prevailing
for commercial loans.
8. Minimum Product Sales
(a) Minimum Amounts - No Volume Limitation. ▇▇▇▇▇▇ agrees to the
establishment of the following minimum Product sales targets in the Territory if
the Product receives FDA approval without volume limitation as specified in
Exhibit E, and subject to ▇▇▇▇▇▇'▇ option not to market the Product as provided
in 8(b) below:
(Confidential Information has been omitted and filed separately with the
Securties and Exchange Commission)
12
▇▇▇▇▇▇ may, at its option, supplement payments due Licensor to make up for any
shortfall between payments due on actual sales and royalty payments due on
target minimums, provided that such supplemental payments shall be made at the
assumed Net Sale price of $100 per liter, or the price expected to optimize Net
Sales as determined by ▇▇▇▇▇▇ market research, whichever is less. Within thirty
(30) days after the end of each 12 month period following the commencement of
Product sales, ▇▇▇▇▇▇ shall deliver to Licensor a report showing the total
number of liters of Product sold in the Territory during such twelve month
period. In the event that ▇▇▇▇▇▇ does not achieve target sales in the Territory
or notify Licensor of its intent to make up shortfalls during such 30 day
period, Licensor has the right to either of the following:
(i) convert ▇▇▇▇▇▇'▇ Exclusive License to a non-exclusive license in
the Territory at no cost to Licensor; or
(ii) buy out and terminate ▇▇▇▇▇▇'▇ Exclusive License (in which case
all of ▇▇▇▇▇▇'▇ rights under the Exclusive License shall immediately
revert back to Licensor) on payment to ▇▇▇▇▇▇ of the amount specified
in (A) or (B), as applicable:
(A) If Licensor exercises the right after the first
anniversary of initiation of sales but before the second
anniversary of initiation of sales, the payment shall be the
sum total of milestone payments made to Licensor.
(B) If Licensor exercises the right after the second
anniversary of initiation of sales, the payment shall be an
amount equal to three times Net Sales of the previous twelve
month period, or the sum total of milestone payments made to
Licensor, whichever is greater.
If Licensor desires to exercise its rights under this paragraph (a) it may do so
by giving ▇▇▇▇▇▇ notice to such effect not later than thirty (30) days after the
later of Licensor's receipt of the report of liters of Product sold or the
expiration of the thirty (30) day period in which ▇▇▇▇▇▇ may retain its
Exclusive License by paying the shortfall in royalty payments. ▇▇▇▇▇▇ shall also
deliver to Licensor a report of total annual Net Sales within ninety (90) days
after the end of each 12 month period following the commencement of Product
sales. If Licensor has exercised its rights under this paragraph (a), it shall
make the payment required by (A) or (B), as applicable, thirty days after
receiving such report of Net Sales.
If ▇▇▇▇▇▇ elects to supplement payments to make up shortfalls as described
above, such payments will be due with License and Royalty payments for the
calendar quarter which includes the anniversary of the initiation of sales.
▇▇▇▇▇▇'▇ failure to achieve target sales and its election not to supplement
payments shall not be a breach of this Agreement.
(b) Decision Not to Market. Prior to the first sale of the Product, or
thirty (30) days after FDA approval of the first NDA for the Product, whichever
comes first, ▇▇▇▇▇▇ may inform Licensor of ▇▇▇▇▇▇'▇ decision not to market the
13
Product. If ▇▇▇▇▇▇ so informs Licensor, ▇▇▇▇▇▇'▇ Exclusive License shall
immediately terminate and revert back to Licensor at no cost to Licensor, and
▇▇▇▇▇▇ agrees to manufacture for, and sell to, Licensor the Product under the
Product Standby Contract Manufacturing Agreement as provided in Article 10 (a),
and ▇▇▇▇▇▇ will do everything necessary to return to Licensor the Exclusive
License. All milestone payments, as described in Article 3, owed will be paid
promptly by ▇▇▇▇▇▇, but ▇▇▇▇▇▇ shall not be obligated to make any milestone
payments to Licensor for milestones that occur after notification by ▇▇▇▇▇▇ to
Licensor of ▇▇▇▇▇▇'▇ decision not to market the Product.
(c) If ▇▇▇▇▇▇'▇ exclusive license for the Product terminates, then
▇▇▇▇▇▇ shall sell to Licensor the Product under the Product Standby Contract
Manufacturing Agreement as provided in Article 10.
(d) In the event that Product receives (or is expected to receive)
regulatory approval with volume limitations, parties agree to enter into good
faith negotiations for Product sales targets. In the event that parties can not
agree on minimum sales targets within ninety days of notification of (expected)
volume limitations, unless otherwise agreed to in writing by the parties, then
Licensor has the right to buy out and terminate ▇▇▇▇▇▇'▇ Exclusive License (in
which case all of ▇▇▇▇▇▇'▇ rights under the Exclusive License shall immediately
revert back to Licensor) on payment to ▇▇▇▇▇▇ of the amount equal to the sum
total of all milestone payments made to Licensor by ▇▇▇▇▇▇, and ▇▇▇▇▇▇ shall
sell to Licensor the Product under the Product Standby Contract Manufacturing
Agreement as provided in Article 10. In no event shall minimum sales targets be
greater than those specified in paragraph (a) above.
9. Patent and Trademark Marking
(a) ▇▇▇▇▇▇ shall label or ▇▇▇▇ each Product or the Product container or
package made by or on behalf of ▇▇▇▇▇▇ with the patent number or numbers of any
issued or pending Licensed Patents. The content, form, location and language
used for such marking shall be in accordance with the laws and practices of each
country in which the Products are sold or the patents have issued or are pending
and in accordance with ▇▇▇▇▇▇'▇ marketing preferences.
(b) ▇▇▇▇▇▇ shall label or ▇▇▇▇ each Product container, package, and
label with the Licensed Trademark and Licensor's name and address. All uses of a
Licensed Trademark shall include (i) the symbol (R) if the Licensed Trademark is
registered with the United States Patent and Trademark Office, (ii) the symbol
TM if the Licensed Trademark is not registered with United States Patent and
Trademark Office, (iii) such symbols or indications of trademark registration or
non-registration as may be comparable under Canadian law to the symbols (R) and
TM, and (iv) a statement that the Licensed Trademark is licensed from Licensor.
(c) ▇▇▇▇▇▇ shall have a reasonable period of time to execute changes to
14
patent and trademark labeling, consistent with any laws or regulations relating
to changes in product labeling, and the reasonable needs of maintaining
efficient manufacturing operations. Updates to patent and trademark labeling are
not required to be made to manufactured product or raw materials in inventory,
or which ▇▇▇▇▇▇ has committed to purchase.
10. Standby Contract Manufacturing Agreement
In the event that ▇▇▇▇▇▇ decides not to market Product, or Licensor
exercises its option to buy out and terminate ▇▇▇▇▇▇'▇ exclusive license as
provided in Article 8, ▇▇▇▇▇▇ and Licensor agree to enter into a mutually
exclusive Standby Contract Manufacturing Agreement for Product, generally
according to terms defined in Exhibit F (the "Product Standby Contract
Manufacturing Agreement"). Upon the request of either party but in any event no
sooner than the date of the NDA submission for the Product, ▇▇▇▇▇▇ and Licensor
will negotiate in good faith and enter into the Product Standby Contract
Manufacturing Agreement with and incorporating all of the principal terms and
conditions set forth on Exhibit F. If the parties do not enter into such
definitive Agreement within ninety (90) days of a request, unless the parties
agree in writing otherwise, the Agreement shall be finalized by the Alternative
Dispute Resolution Process of Exhibit G such that it is consistent with and
incorporates all of the principal terms and conditions set forth on Exhibit F,
and contains such other terms and conditions that are usual and customary for
contract manufacturing arrangements in the industry, and enforceable in
accordance with their terms.
11. Right of First Refusal - New Products
(a) Grant. Licensor grants ▇▇▇▇▇▇ a right of first refusal to obtain an
Exclusive License in the Territory to make, have made and sell New Products that
Licensor develops for use at Normothermic Temperatures in the field of plasma
volume expansion. Such Exclusive License will be on substantially the same terms
and conditions as this Agreement, except as otherwise provided in this Article
11.
(Confidential Information has been omitted and filed separately with the
Securties and Exchange Commission)
15
(Confidential Information has been omitted and filed separately with the
Securties and Exchange Commission)
(d) New Product Standby Contract Manufacturing Agreement. On the
request of either party, but in any case no sooner than notification by Licensor
16
to ▇▇▇▇▇▇ of the first successful use of the New Product in a phase II or higher
clinical trial, ▇▇▇▇▇▇ and Licensor will enter into negotiations for a Standby
Contract Manufacturing Agreement for New Product. If a New Product Standby
Contract Manufacturing Agreement is successfully negotiated, and ▇▇▇▇▇▇ does not
exercise its right to obtain the Exclusive License in the manner and time
provided in paragraph (c) above, it will contract manufacture the New Product
for Licensor as provided in the Agreement negotiated. If the parties do not
enter into such definitive Standby Contract Manufacturing Agreement for New
Product within ninety (90) days of a request, unless the parties agree in
writing otherwise, Licensor shall be free to license the New Product to Third
Persons or take any and all other actions with respect to New Product provided
that:
(i) Unless previously paid for by Licensor under the terms of paragraph
(b) above, Licensor will reimburse ▇▇▇▇▇▇ for its reasonable expenses
in providing materials, data and other support for clinical trials of
New Product. ▇▇▇▇▇▇ will provide Licensor with stability study data,
drug master file access, manufacturing information in the form of a
batch record or its equivalent, certificates of analysis and any other
documentation and information developed by ▇▇▇▇▇▇ which is needed by
Licensor to obtain regulatory approval for its New Product.
(ii) if Licensor offers New Product to a Third Person for license or
contract manufacture on terms more favorable than those offered to
▇▇▇▇▇▇, ▇▇▇▇▇▇ has the right to accept such more favorable terms
within forty-five (45) days of notice by Licensor to ▇▇▇▇▇▇. If ▇▇▇▇▇▇
does not exercise its rights within the 45 day period, then ▇▇▇▇▇▇
shall have no further rights in connection with the New Product.
(Confidential Information has been omitted and filed separately with the
Securties and Exchange Commission)
(f) Total Body Washout. During the nine month period commencing on the
date Licensor notifies ▇▇▇▇▇▇ that a successful Total Body Washout has been
performed in a phase II/III clinical trial, or the ninety day period after
notification of completion of phase II clinical trials using the Product or any
New Product developed by Licensor in Total Body Washout, whichever is longer,
▇▇▇▇▇▇ shall have the exclusive right to negotiate with Licensor for an
Exclusive License to make, have made, and sell such Product or New Product in
the Territory for use in Total Body Washout or at temperatures lower than
Normothermic Use; provided that such right shall expire sixty (60) days after
17
such notice from Licensor unless within such sixty (60) day period ▇▇▇▇▇▇
notifies Licensor of ▇▇▇▇▇▇'▇ desire to engage in such negotiations. If ▇▇▇▇▇▇
elects to engage in such negotiations, the parties shall negotiate in good
faith. The terms and provisions of this Agreement, other than this paragraph and
the provisions pertaining to royalties, shall not control the terms and
conditions of any agreement pertaining to a license of such Product or New
Product. If a binding, written agreement is not executed within such nine month
period, Licensor shall be free to (i) use Licensed Patents, Proprietary Rights,
and all other rights (excluding Trademarks already licensed to ▇▇▇▇▇▇) to make,
have made, and sell such Product or New Product in packaging containing more
than two liters of product for use in Total Body Washout or at temperatures
lower than Normothermic Use, or (ii) sell, assign, transfer and license to Third
Parties Licensed Patents, Proprietary Rights, and all other rights (excluding
Trademarks already licensed to ▇▇▇▇▇▇) to make, have made and sell such Product
or New Product in packaging containing more than two liters of product (net
contents) for use in Total Body Washout or at temperatures lower than
Normothermic Use, provided that if Licensor offers Total Body Washout Product to
a third Person for license or contract manufacture on terms more favorable than
those offered to ▇▇▇▇▇▇, ▇▇▇▇▇▇ has the right to accept such more favorable
terms within forty-five (45) days of notice to Licensor by ▇▇▇▇▇▇. If ▇▇▇▇▇▇
does not exercise its rights within the 45 day period, then ▇▇▇▇▇▇ shall have no
further rights in connection with such Product or New Product for use in Total
Body Washout. In addition, Licensor agrees to:
(i) exclude uses licensed to ▇▇▇▇▇▇ from indications requested in its
regulatory applications for Total Body Washout and/or lower than
Normothermic Use product, within the Territory.
(ii) require that any party selling Total Body Washout and/or lower
than Normothermic Use product within the territory agree not to
promote or support use of said product for uses licensed to
▇▇▇▇▇▇, on penalty of revocation of their license for said
product.
(iii) in the event that the requirements of (ii) above continue to be
violated 60 days after notification to Licensor by ▇▇▇▇▇▇,
Licensor will revoke the license of said party, and take all
actions necessary to end sale of said product by that party in
the Territory.
(g) Expiration of Right of First Refusal. ▇▇▇▇▇▇'▇ rights under this
Article 11 will expire automatically at such time, if any, as ▇▇▇▇▇▇ ceases to
have at least one of the following: (i) an Exclusive License in the Territory to
make, have made and sell the Product, an Improved Product or a New Product; or
(ii) a pending, unexpired right (preserved by ▇▇▇▇▇▇'▇ performance under
paragraph (b) above) to acquire an Exclusive License to a New Product upon
notice to Licensor under paragraph (c) above.
(h) Agreement Modifications on Licensing of a New Product. If a New
Product is licensed by ▇▇▇▇▇▇ under this Agreement, the New Product will be
deemed a "Product" as defined in this Agreement, and the terms "Licensed
Patents," "Proprietary Rights" and "Licensed Trademarks" shall include those
intellectual property rights pertaining to the New Product; provided, however,
that the minimum sales targets in Article 8 shall be revised equitably by the
parties in good faith, and if the parties cannot agree on such revision, the new
minimum sales targets shall be determined by Alternative Dispute Resolution (as
provided in Exhibit G) applying standards comparable to the those applicable to
the original Product.
18
12. Infringement and Indemnification
(a) Infringement by Third Person. In the event Licensor or ▇▇▇▇▇▇ have
reason to believe that a Third Person may be infringing or misappropriating any
of the Licensed Patents or Proprietary Rights, or infringing, misappropriating
or diluting any Licensed Trademark, such party shall promptly notify the other
party. Licensor may, in its discretion, elect to enforce the Licensed Patents,
Proprietary Rights or Licensed Trademarks, through legal action or otherwise,
and ▇▇▇▇▇▇ agrees to reasonably cooperate with Licensor in such enforcement. At
all times in any such enforcement action, Licensor and its counsel shall retain
control of the litigation. Licensor shall be entitled to retain recovery which
may be obtained in any lawsuit brought by Licensor. In the event Licensor elects
not to enforce the Licensed Patents within three (3) months after notice of the
possible infringement is given between Licensor and ▇▇▇▇▇▇, ▇▇▇▇▇▇ may
discontinue the payment in such country by 50% until such time as the
infringement of the Licensed Patents ceases and/or may thereafter institute a
lawsuit at its expense to prevent continuation of such potential infringement.
To the extent that any award of damages or other compensation obtained by ▇▇▇▇▇▇
in any lawsuit brought by ▇▇▇▇▇▇ exceeds ▇▇▇▇▇▇'▇ direct costs of litigation,
such excess shall be treated as Net Sales upon which a royalty and license fee
shall be paid to Licensor. Licensor will provide reasonable cooperation with
respect to any lawsuit which ▇▇▇▇▇▇ may bring pursuant to this Article 12.
(b) Alleged Infringement of Third Person Patents.
(i) If a claim or lawsuit is brought against ▇▇▇▇▇▇ alleging
infringement of any patent or infringement or dilution of any trademark
owned by a Third Person arising from ▇▇▇▇▇▇'▇ manufacture, use sale,
offer for sale, or importing of the Product or any Improved Product or
use of Proprietary Rights, ▇▇▇▇▇▇ shall promptly give written notice to
Licensor of such claim or lawsuit and provide to Licensor all
information in ▇▇▇▇▇▇'▇ possession regarding such claim or lawsuit.
Within a reasonable time after receiving notice of such claim or
lawsuit, but in any event within sixty (60) days after receiving such
notice, Licensor shall advise ▇▇▇▇▇▇ of Licensor's decision as to what
action it plans to take to dispose of such claim or defend such
lawsuit.
(ii) Licensor shall defend, indemnify and hold ▇▇▇▇▇▇
harmless against any judgment, damage, liability, loss, cost or other
expense (including reasonable legal fees) resulting from any claim or
lawsuit which relates to or arises out of the alleged infringement by
▇▇▇▇▇▇ of any patent owned by a Third Person to the extent that the
alleged infringement relates to actions covered by the Exclusive
License granted to ▇▇▇▇▇▇; provided that, ▇▇▇▇▇▇ shall promptly give
notice to Licensor of any such claim or lawsuit, shall provide to
Licensor all information in ▇▇▇▇▇▇'▇ possession regarding such claim or
lawsuit, and shall provide Licensor such reasonable assistance as
Licensor may, from time to time, reasonably request; provided, that
19
Licensor shall have no obligation to indemnify or defend ▇▇▇▇▇▇ against
any claim or lawsuit pertaining to ▇▇▇▇▇▇'▇ use of any technology,
method, process, device, or equipment in connection with manufacturing
or packaging that was developed by ▇▇▇▇▇▇ or obtained by ▇▇▇▇▇▇ from a
Third Person. Furthermore, if Licensor notifies ▇▇▇▇▇▇ to discontinue
manufacturing and/or selling any product because of a potential
infringement, then any liability for such infringement following such
notice shall be solely for ▇▇▇▇▇▇'▇ account and shall not be
indemnified by Licensor. Net sales of any product after date of such
notification will not be included in any calculations of payments due
Licensor. Licensor, at its option and expense, may dispose of such
claim or may conduct the defense of such lawsuit. Licensor's liability
to ▇▇▇▇▇▇ for indemnification with respect to any and all infringement
claims or lawsuits shall not exceed the aggregate amount of all license
fees and royalties previously paid to Licensor by ▇▇▇▇▇▇.
(iii) If Licensor disposes of a claim or conducts the
defense of a lawsuit for which it is obligated to indemnify ▇▇▇▇▇▇
pursuant to Article 12 (b)(ii) without directing ▇▇▇▇▇▇ to discontinue
manufacture or sale of product, there shall be no abatement of the
applicable royalties payable for such Product or Improved Product in
the country where such claim or lawsuit is brought during the pendency
of such disposition or lawsuit or any appeal taken from it. If Licensor
elects not to dispose of such claim or defend such lawsuit, ▇▇▇▇▇▇ may
defend the claim or lawsuit. For purposes of ▇▇▇▇▇▇'▇ conduct of the
disposition or defense, Licensor shall furnish to ▇▇▇▇▇▇ such
reasonable assistance as ▇▇▇▇▇▇ may need and from time to time
reasonably request. If ▇▇▇▇▇▇ takes on the disposition of a claim or
defense of a lawsuit for which Licensor is obligated to indemnify
▇▇▇▇▇▇ pursuant to Article 12(b)(ii), then the payments for such
Product in such country, which would otherwise be payable to Licensor
hereunder, shall be reduced by 50% during the pendency of such lawsuit
or any appeal taken from it. Upon final resolution of the above
described claim, lawsuit and/or appeal, ▇▇▇▇▇▇ shall resume paying
Licensor any royalties or license payments payable hereunder, but in no
event shall ▇▇▇▇▇▇ be liable for back royalties or license payments
hereunder.
(iv) If ▇▇▇▇▇▇ becomes obligated to pay royalties to any
Third Person, in order to make, have made, or sell the Product in the
Territory, said royalties shall be creditable against royalties
otherwise payable to Licensor hereunder; provided, that no such credit
shall be allowed with respect to any royalty paid for the use of any
technology, method, process, device, or equipment in connection with
manufacturing, packaging or any container or delivery system, or the
use of any trademark, that was developed by ▇▇▇▇▇▇, any Affiliate or
any sublicensee or obtained from a Third Person.
(c) By Licensor. Licensor shall defend, indemnify and hold ▇▇▇▇▇▇
harmless against any liability, damage, loss, cost or expense, including
reasonable legal fees ("Liability") arising out of or resulting from: (i) any
Third Person claims or lawsuits made or brought against ▇▇▇▇▇▇, any Affiliate or
sublicensee, or any of their respective employees, agents or contractors, to the
extent such Liability arises out of or relates to negligence or willful
20
misconduct of Licensor, or any of its employees, agents or contractors, with
regard to clinical trials or testing of the Product or any Improved Product, the
preparation and filing of FDA Applications, the maintenance of NDAs, product
labeling, reporting required by the FDA, or any other negligent or wrongful act
or omission of Licensor: (ii) any failure of Licensor or any of its employees,
agents or contractors to comply with any applicable law, rule or regulation and
(iii) Licensor's breach of, or failure to comply with any representations,
warranties, covenants or obligations of this Agreement.
(d) By ▇▇▇▇▇▇. ▇▇▇▇▇▇ shall defend, indemnify and hold Licensor
harmless against any liability, damage, loss, cost or expense, including
reasonable legal fees ("Liability"), arising out of or resulting from: (i) any
Third Person claims or lawsuits made or brought against Licensor, or any of its
employees, agents or contractors, to the extent such Liability arises out of or
relates to negligence or willful misconduct of ▇▇▇▇▇▇, any Affiliate or
sublicensee, or any of their respective employees, agents or contractors, with
regard to the manufacture, use, testing, storage, promotion, shipment, handling,
labeling, distribution or sale of, or other negligent or wrongful act or
omission with respect to, the Product, any Improved Product, or any container,
packaging or delivery system of the Product or any Improved Product, or the use
of the Proprietary Rights; (ii) any failure of ▇▇▇▇▇▇, any Affiliate or
sublicensee, or any of their respective employees, agents or contractors to
comply with any applicable law, rule or regulation; or (iii) ▇▇▇▇▇▇'▇ breach of,
or failure to perform or comply with, any of its representations, warranties,
covenants and obligations under this Agreement.
(e) Conditions to Indemnification. The agreement of the parties to
indemnify each other, as provided in this Article 12, is conditioned upon the
indemnified party's obligation to: (i) advise the indemnifying party (If ▇▇▇▇▇▇:
▇▇▇▇▇▇ Laboratories, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇,
Attention: Risk Management, D-317; and if Licensor: BioTime, Inc., ▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇, Attention: President) of any claim or
lawsuit, in writing, within five (5) days after the indemnified party has
received notice of said claim or lawsuit or within such a time frame as not to
materially prejudice the rights of the indemnifying party and (ii) assist the
indemnifying party and its representatives in the investigation and defense of
any claim and/or lawsuit for which indemnification is provided. The agreement of
the parties to indemnify each other shall not be valid as to any settlement of a
claim or lawsuit or offer of settlement or compromise without the prior written
approval of the indemnifying party.
(f) Limit on Consequential Damages. Notwithstanding any other provision
of this Agreement, neither party shall be liable to the other for any
consequential, incidental, special or indirect damages whatsoever, unless they
are allowed Third Person damages against which one party is to indemnify the
other.
21
13. Confidentiality
(a) Confidentiality. Neither party shall use or disclose any
Confidential Information received by it pursuant to this Agreement without the
prior written consent of the other. This obligation will continue for a period
of three (3) years after expiration or prior termination of this Agreement. If a
party received Confidential Information from the other party, the receiving
party shall maintain and protect the secrecy of such Confidential Information in
a manner consistent with the manner in which the receiving party protects its
own Confidential Information.
(b) Disclosure. Nothing contained in this Article shall be construed to
restrict the parties from disclosing Confidential Information as required:
(I) For regulatory, tax or customs reasons;
(ii) For audit purposes;
(iii) By Court order or other government order or request
as long as reasonable efforts have been made to
assure its confidentiality or the other party is
timely notified to make such efforts; or
(iv) To perform acts permitted by this Agreement.
14. Term and Termination
(a) Term. Unless otherwise terminated as herein provided, this
Agreement shall commence on the Effective Date and shall expire on a product by
product and country-by-country basis in the Territory upon expiration of
▇▇▇▇▇▇'▇ obligation to pay Licensor royalties for Net Sales of that product.
▇▇▇▇▇▇ agrees not to market a generic equivalent of any Product or Improved
Product in the Territory before the expiration of this Agreement.
(b) Early Termination. A party may terminate this Agreement
(including all Exclusive Licenses) by giving to the other party sixty (60)
days prior written notice as follows:
(i) Upon the bankruptcy or the insolvency of the other party; or
(ii) Upon the breach of any material provision of this
Agreement by the other party if the breach is not cured
within sixty (60) days after written notice thereof to the
party in default.
(c) Consequences of Termination.
(i) Survival of Liability. Termination, expiration,
cancellation or abandonment of this Agreement through any
means and for any reason shall not relieve the parties of
any obligation accruing prior thereto and shall be without
prejudice to the rights and remedies of either party with
respect to any antecedent breach of any of the provisions of
this Agreement.
22
(ii) Return of Confidential Information. Upon termination of
this Agreement for any reason before the expiration of the
Licensed Patents or the expiration of the Agreement, each
party shall, upon request by the other party, return to the
requesting party all copies of the requesting party's
Confidential Information and shall make no further use
thereof.
(d) Fully Paid-Up License. Upon expiration of ▇▇▇▇▇▇'▇ obligation to
pay Licensor royalties for a Product or Improved Product, on a country by
country and product by product basis, ▇▇▇▇▇▇'▇ license under the Licensed
Patents and Proprietary Rights shall become fully paid-up and irrevocable for
that product and in that country.
15. Representations and Warranties of Licensor
Licensor represents and warrants that:
(a) Licensor has the full right and power to perform the obligations
and grant the Exclusive License set forth in this Agreement, and there are no
outstanding agreements, assignments or encumbrances in existence inconsistent
with the provisions of this Agreement;
(b) The Licensed Patents and/or Proprietary Rights have not knowingly
been obtained through any activity, omission or representation that would
significantly limit or destroy the validity of the Licensed Patents and/or
Proprietary Rights, and the Licensor has no knowledge or information that would
materially adversely impact the validity and/or enforceability of the existing
Licensed Patents and/or Proprietary Rights;
(c) To the best of Licensor's knowledge, there are no actions,
threatened or pending, before any court relating to the Licensed Patents and/or
Proprietary Rights;
(d) Licensor has not authorized others to practice the Licensed
Patents and/or Proprietary Rights;
(e) Licensor owns and possesses all right, title and interest in and to
the Licensed Patents and/or Proprietary Rights and, to the best of Licensor's
knowledge, no Third Person has acquired, owns or possesses any right, title or
interest in or to the Licensed Patents and/or Proprietary Rights;
(f) Licensor has no agreement with any Third Person which (i) gives any
rights to such Third Person, or (ii) imposes obligations upon Licensor which, in
either case, would adversely affect the rights of Abbott or the obligations of
Licensor under this Agreement;
(g) Exhibit B lists all United States and Canadian patents issued and
23
patent applications filed by Licensor on or before the Effective Date within the
scope of the Licensed Patents and hence subject to this Agreement, and all of
the inventors named in the patents and patent applications listed in Exhibit B
have assigned, or are under an obligation to assign, to Licensor all of their
right, title and interest in the inventions claimed; and,
(h) This Agreement has been duly authorized, executed and delivered by
Licensor and is the valid and binding agreement of Licensor, enforceable in
accordance with its terms.
16. Representations and Warranties of ▇▇▇▇▇▇
▇▇▇▇▇▇ represents and warrants that:
(a) This Agreement has been duly authorized, executed and delivered by
Abbott and is the valid and binding agreement of Abbott, enforceable in
accordance with its terms.
(b) The execution and delivery of this Agreement does not, and
manufacture and sale of the Product by Abbott will not (a) violate the terms of
any order, writ or decree of any court or judicial or regulatory authority or
body, or (b) conflict with or result in a breach of any condition or provision
or constitute a default under or pursuant to the terms of any contract, license,
or agreement to which Abbott or any Affiliate is a party, or which is or
purports to be binding upon Abbott or any Affiliate, or upon any of the
properties or assets of Abbott or any Affiliate.
(c) Abbott has no knowledge or information that would lead Abbott to
believe that the existing Licensed Patents and/or Proprietary Rights are not
valid or enforceable;
(d) Abbott has or will maintain access to a supply of High Molecular
Weigh Hetastarch sufficient to meet market demand for the Product.
(e) Abbott has or will maintain access to manufacturing facilities
capable of producing a sufficient quantity of the Product, under good
manufacturing practices, to meet market demand.
(f) Abbott, its Affiliates and sublicensees, and their respective
employees, agents and contractors, will manufacture the Product under good
manufacturing practices, in compliance with all applicable laws, statutes, rules
and regulations.
(g) ▇▇▇▇▇▇, its Affiliates and sublicensees will distribute, market,
sell, transport and dispose of the Product in compliance with all applicable
laws, statutes, rules and regulations.
(h) Abbott shall provide Licensor promptly in writing all adverse
events and safety data which Abbott or its Affiliates or sublicensees obtain
concerning the Product and Improved Products.
24
17. Notices
All notices given under this Agreement shall be in writing and shall be
delivered personally, by facsimile confirmed by postage prepaid first-class
mail, by over-night or next business day air courier, or by postage prepaid
certified mail to the following addresses of the respective parties:
▇▇▇▇▇▇ Laboratories
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇
Attention: General Counsel
With copy to: President, Hospital Products Division
BioTime, Inc.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: President
With copy to: Chief Financial Officer
Notices shall be effective upon receipt if personally delivered or
delivered by facsimile or air courier, or on the third business day following
the date of mailing. A party may change its address and designates listed above
by notice to the other party.
18. Alternative Dispute Resolution
The parties recognize that bona fide disputes may arise which relate to
the parties' rights and obligations under this Agreement. The parties agree that
any such dispute shall be resolved by Alternative Dispute Resolution (ADR) in
accordance with the procedures set forth in Exhibit G.
19. Publicity
The parties agree that subsequent to the execution of this Agreement, a
press release approved by both parties will be issued. Except for such press
release and periodic disclosures required by law or regulation or in the
ordinary course of its SEC filings, neither party shall (i) originate any
publicity, news release or other public announcement, written or oral, whether
to the public press, stockholders or otherwise, relating to this Agreement, any
amendment hereto or performance hereunder, or (ii) use the name of the other in
any publicity, news release or other public announcement, except (a) with the
prior written consent of the other party, or (b) as required by law, in which
case the originating party will give to the other party at least seven (7) days
25
prior notice of such proposed disclosure to complete a review in order to offer
comments and modifications. Consistent with applicable law, the other party will
have the right to request reasonable changes to the disclosure to protect its
interests. In all other cases, the originating party shall give the consenting
party at least fourteen (14) days to complete a review in order to offer
comments, modifications or to give such consent. The party required to give
consent shall endeavor to respond in less than fourteen (14) days if
practicable.
20. Applicable Law
This Agreement shall be governed by and interpreted in accordance with
the laws of the State of California, regardless of the choice of law principles
of California or any other jurisdiction.
21. Assignment
Neither party shall assign this Agreement or any part thereof without
the prior written consent of the other party; provided, however, that without
the consent of the other party (a) Abbott may assign this Agreement to a wholly
owned Abbott subsidiary; provided that under the terms of such assignment this
Agreement or the rights and obligations so assigned shall revert back to Abbott
immediately before ▇▇▇▇▇▇'▇ disposition of a controlling interest in such
subsidiary, (b) Licensor may assign this Agreement to a wholly owned subsidiary
of Licensor; provided that under the terms of such assignment this Agreement or
the rights and obligations so assigned shall revert back to Licensor immediately
before Licensor's disposition of a controlling interest in such subsidiary, (c)
Licensor may assign its rights to receive license fees or royalty payments, and
(d) either party may assign or sell its rights and obligations under this
Agreement in connection with the transfer or sale of substantially its entire
business to which this Agreement pertains (which in the case of Abbott means its
hospital products division) or through a merger or consolidation with another
company. Any permitted assignee (other than an assignee of a right to receive
payments due Licensor) shall assume all obligations of its assignor under this
Agreement. No assignment shall relieve any party of responsibility for the
performance of any obligation which such party has hereunder.
22. Entire Agreement
This Agreement and the Exhibits constitute the entire agreement between
the parties concerning the subject matter hereof and supersede all written or
oral prior agreements or understandings with respect thereto. No course of
dealing or usage of trade shall be used to modify the terms and conditions
hereof.
23. Severability
This Agreement is subject to the restrictions, limitations, terms and
conditions of all applicable laws, governmental regulations, approvals and
clearances. If any term or provision of this Agreement shall for any reason be
held invalid, illegal or unenforceable in any respect, such invalid, illegal or
26
unenforceable provision shall be modified so as to conform to the applicable
requirements, and this Agreement shall be modified by the parties so as to
accomplish as nearly as possible the original intention of the parties
consistent with applicable laws and regulations.
24. Cumulative Rights and Remedies
The rights, powers, and remedies given to each party under this
Agreement shall be cumulative and in addition to all rights, powers, and
remedies given to such party by virtue of any statute or rule of law. The
exercise or existence of any right or remedy under this Agreement shall not
preclude the exercise of any other right or remedy or constitute an election of
remedies, and any forbearance or failure or delay in exercising any right,
power, or remedy shall not preclude the further exercise thereof or any other.
25. Waiver - Modification of Agreement
No waiver or modification of any of the terms of this Agreement shall
be valid unless in writing and signed by authorized representatives of the party
to be charged. Failure or delay by either party to enforce any rights under this
Agreement shall not be construed as a waiver of such rights nor shall a waiver
by either party in one or more instances be construed as constituting a
continuing waiver or as a waiver in other instances.
The parties intending to be bound by the terms and conditions hereof
have caused this Agreement to be signed by their duly authorized representatives
on the date first above written.
▇▇▇▇▇▇ LABORATORIES BIOTIME, INC.
By:____________________________ By:___________________________
Title:_________________________ Title:________________________
27
BIOTIME, INC.
AND
▇▇▇▇▇▇ LABORATORIES
Exclusive License Agreement
Exhibit A Hextend(R) Formulation
(Confidential information has been omitted and filed separately with the
Securities and Exchange Commission)
28
BIOTIME, INC.
AND
▇▇▇▇▇▇ LABORATORIES
Exclusive License Agreement
Exhibit B Patent Rights
United States Patent 5,407,428
Solutions for Use as Plasma Expanders and Substitutes
United States Serial Number 08/253,384, filed 6/3/94
"Plasma-Like Solution"
United States Serial Number 08/364,699, filed 12/28/94
"Plasma Expanders and Blood Substitutes"
Canadian Patent Application Serial Number 2,066,374, filed 4/17/92
"Solutions"
Canadian Patent Application Serial Number 2,164,321, filed 6/3/94
"Plasma Like Solution"
29
BIOTIME, INC.
AND
▇▇▇▇▇▇ LABORATORIES
Exclusive License Agreement
Exhibit C Milestone Payments and Sales Related License Fees
Milestone Payments:
The following milestone payments are due within forty-five (45) days
after Licensor gives Abbott notice of achievement of the milestone:
1. On signing of this agreement, $1,000,000
2. On verification to Abbott of payment by Licensor of the issue fee for USSN
253,384 having at a minimum claims directed to the composition of matter
described in Exhibit C.1., $400,000. Provided however, that in the event
that the patent does not issue within nine (9) months from the date on
which the issue fee was paid, Abbott will withhold $400,000 from future
payments due Licensor until the issuance of the patent.
3. On notification to Abbott of submission of an NDA for Abbott manufactured
Product for FDA approval, $250,000
4. On notification to Abbott of FDA approval of an NDA for Abbott manufactured
Product, $250,000
5. If the above approval contains no language implicitly or explicitly
limiting maximum dosage as described in Exhibit E, $500,000 (which $500,000
shall be in addition to the $250,000 under paragraph 4)
6. On first sale of Product under this agreement, $100,000
Sales Related License Fees
Licensee will pay Licensor up to $37.5 Million dollars in sales related
license fees calculated as follows:
1. For every year in which Net Sales equal or exceed $30 Million, an amount
equal to 10% of Net Sales for such year.
30
2. For every year in which Net Sales are between $15 Million and $30 Million,
an amount equal to 5% of Net Sales for such year.
3. No sales related license fees shall be are due for sales made after
January 1, 2007.
31
BIOTIME, INC.
AND
▇▇▇▇▇▇ LABORATORIES
Exclusive License Agreement
Exhibit C.1 Composition of Matter, Minimum Claims
(Confidential Information has been omitted and filed separately with the
Securities and Exchange Commission, 2 pages)
32
BIOTIME, INC.
AND
▇▇▇▇▇▇ LABORATORIES
Exclusive License Agreement
Exhibit D Royalties
Royalties
Licensee will pay Licensor royalties at least equal to 5%, but no more than 36%
of Net Sales during the term of this Agreement, determined as follows:
1. Royalty percentage rate is equal to 5.0% plus an additional 0.22% for
every million dollars of annual Net Sales
2. Royalties are equal to the royalty percentage rate determined in 1.
above, multiplied by annual Net Sales.
33
BIOTIME, INC.
AND
▇▇▇▇▇▇ LABORATORIES
Exclusive License Agreement
Exhibit D.1 Calculation of License Fee and Royalty Payments
In determining royalties and license fees payable based upon annualized Net
Sales for each three month period (calendar quarter), the following procedure
shall apply:
(i) the sum of actual Net Sales for the applicable calendar quarter
plus actual Net Sales for all previous calendar quarters of the calendar year
shall be divided by a fraction, the numerator of which is the number of months
that have elapsed in the calendar year, and the denominator of which is 12;
(ii) the amount determined in (i) shall be multiplied by applicable
royalty rate shown on Exhibit D or license fee rate shown on Exhibit C, as
applicable;
(iii) the amount determined in (ii) shall be multiplied by a fraction,
the numerator of which is the number of months that have elapsed in the calendar
year, and the denominator of which is 12; and
(iv) the sum of all royalties or license fees, as applicable,
previously paid on account of Net Sales for such calendar year shall be deducted
from the amount determined in (iii).
If the amount payable in accordance with the previous sentence is a negative
number after the fourth quarter of a calendar year, the amount of such excess
payment shall be credited against royalty or license fees, as applicable,
payable by Abbott during the next calendar year. Payments made (or due to be
made) during the first quarter of a calendar year on account of Net Sales for
the previous calendar year shall not be included in determining royalty or
license fees paid on account of Net Sales for a calendar year.
34
BIOTIME, INC.
AND
▇▇▇▇▇▇ LABORATORIES
Exclusive License Agreement
Exhibit E No Volume Limitation
(Confidential information has been omitted and filed separately with the
Securities and Exchange Commission)
35
BIOTIME, INC.
AND
▇▇▇▇▇▇ LABORATORIES
Exclusive License Agreement
Exhibit F Product Standby Contract Manufacturing Agreement
(Confidential information has been omitted and filed separately with the
Securities and Exchange Commission)
3. Unit price of the Product (separate from the price of the High
Molecular Weight Hetastarch) will be adjusted for inflation based upon the
Producer Price Index, Pharmaceutical Preparations, ethical (Prescription)
commodity code 06-35, issued by the Bureau of Labor Statistics, U.S. Department
of Labor, , with the base year beginning January 1, 1997.
4. The minimum annual quantity to be produced by Abbott and purchased
by Licensor is 100,000 units; provided, that Licensor shall not be obligated to
purchase any quantity during any calendar year in which ▇▇▇▇▇▇'▇ Exclusive
License is in effect.
(Confidential information has been omitted and filed separately with the
Securities and Exchange Commission)
36
6. The foregoing price terms apply through the year 2010. After the
year 2010, either party may request good faith renegotiation of the contract
manufacturing price. If the parties cannot agree on a new price, the price will
be determined through Alternative Dispute Resolution per Exhibit G.
7. Price applies to Product contained in ▇▇▇▇▇▇'▇ standard vinyl IV
bag. If a major change in the container or manufacturing process is required by
a party with regulatory authority (meaning a change in container design or
manufacturing process of significant magnitude to require prior approval by a
regulatory body), Abbott and Licensor will negotiate a new price arrangement in
good faith, and if the parties cannot agree on such price arrangement, it shall
be determined by Alternative Dispute Resolution (as provided in Exhibit G) which
shall fairly and equitably allocate the actual cost increase resulting from such
FDA mandated change.
8. Abbott agrees, in the Territory, to contract manufacture Product or
Improved Product only for Licensor. Licensor agrees to contract only with Abbott
for manufacture of Product or Improved Product for sale in the Territory.
Licensor will not license any other manufacturer to make a product for sale in
the Territory which is being manufactured by Abbott for Licensor, so long as
Abbott is able to meet market demand.
9. The contract manufacturing agreement can be terminated either by
Abbott or Licensor five years after the agreement has gone into effect or any
time thereafter, provided two years notice has been provided to the other party,
or at any time by mutual consent of Abbott and Licensor.
37
BIOTIME, INC.
AND
▇▇▇▇▇▇ LABORATORIES
Exclusive License Agreement
Exhibit G Alternative Dispute Resolution
The parties recognize that bona fide disputes as to certain matters may arise
from time to time during the term of this Agreement which relate to either
party's rights and/or obligations. To have such a dispute resolved by this
Alternative Dispute Resolution ("ADR") provision, a party first must send
written notice of the dispute to the other party for attempted resolution by
good faith negotiations between their respective presidents (or their
equivalents) of the affected subsidiaries, divisions, or business units (all
references to "days" in this ADR provision are to calendar days).
If the matter has not been resolved within twenty-eight (28) days of the notice
of dispute, or if the parties fail to meet within such twenty-eight (28) days,
either party may initiate an ADR proceeding as provided herein. The parties
shall have the right to be represented by counsel in such a proceeding.
1. To begin an ADR proceeding, a party shall provide written notice to the
other party of the issues to be resolved by ADR. Within fourteen (14)
days after its receipt of such notice, the other party may, by written
notice to the party initiating the ADR, add additional issues to be
resolved within the same ADR.
2. Within twenty-one (21) days following receipt of the original ADR notice,
the parties shall select a mutually acceptable neutral to preside in the
resolution of any disputes in this ADR proceeding. If the parties are
unable to agree on a mutually acceptable neutral within such period,
either party may request the President of the CPR Institute for Dispute
Resolution ("CPR"), ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇
▇▇▇▇▇, to select a neutral pursuant to the following procedures:
(a) The CPR shall submit to the parties a list of not less than five
(5) candidates within fourteen (14) days after receipt of the
request, along with a Curriculum Vitae for each candidate. No
candidate shall be an employee, director, or shareholder of
either party or any of their subsidiaries or affiliates.
(b) Such list shall include a statement of disclosure by each
candidate of any circumstances likely to affect his or her
impartiality.
38
(c) Each party shall number the candidates in order of preference
(with the number one (1) signifying the greatest preference) and
shall deliver the list to the CPR within seven (7) days
following receipt of the list of candidates. If a party believes
a conflict of interest exists regarding any of the candidates,
that party shall provide a written explanation of the conflict
to the CPR along with its list showing its order of preference
for the candidates. Any party failing to return a list of
preferences on time shall be deemed to have no order of
preference.
(d) If the parties collectively have identified fewer than three (3)
candidates deemed to have conflicts, the CPR immediately shall
designate as the neutral the candidate for whom the parties
collectively have indicated the greatest preference. If a tie
should result between two candidates, the CPR may designate
either candidate. If the parties collectively have identified
three (3) or more candidates deemed to have conflicts, the CPR
shall review the explanations regarding conflicts and, in its
sole discretion, may either (i) immediately designate as the
neutral the candidate for whom the parties collectively have
indicated the greatest preference, or (ii) issue a new list of
not less than five (5) candidates, in which case the procedures
set forth in subparagraphs 2(a) - 2(d) shall be repeated.
3. No earlier than twenty-eight (28) days or later than fifty-six (56) days
after selection, the neutral shall hold a hearing to resolve each of the
issues identified by the parties. The ADR proceeding shall take place at
a location agreed upon by the parties. If the parties cannot agree, the
neutral shall designate a location other than the principal place of
business of either party or any of their subsidiaries or affiliates.
4. At least seven (7) days prior to the hearing, each party shall submit the
following to the other party and the neutral:
(a) a copy of all exhibits on which such party intends to rely in
any oral or written presentation to the neutral;
(b) a list of any witnesses such party intends to call at the
hearing, and a short summary of the anticipated testimony of
each witness;
(c) a proposed ruling on each issue to be resolved, together with a
request for a specific damage award or other remedy for each
issue. The proposed rulings and remedies shall not contain any
recitation of the facts or any legal arguments and shall not
exceed one (1) page per issue.
(d) a brief in support of such party's proposed rulings and
remedies, provided that the brief shall not exceed twenty (20)
pages. This page limitation shall apply regardless of the number
of issues raised in the ADR proceeding.
39
Except as expressly set forth in subparagraphs 4(a) - 4(d) and except
that each party shall be entitled to take up to five (5) depositions
(lasting no longer than three (3) hours per deposition), no discovery
shall be required or permitted by any other means, including
interrogatories, requests for admissions, or production of documents.
5. The hearing shall be conducted on two (2) consecutive days and shall be
governed by the following rules:
(a) Each party shall be entitled to five (5) hours of hearing time
to present its case. The neutral shall determine whether each
party has had the five (5) hours to which it is entitled.
(b) Each party shall be entitled, but not required, to make an
opening statement, to present regular and rebuttal testimony,
documents or other evidence, to cross-examine witnesses, and to
make a closing argument. Cross-examination of witnesses shall
occur immediately after their direct testimony, and
cross-examination time shall be charged against the party
conducting the cross-examination.
(c) The party initiating the ADR shall begin the hearing and, if it
chooses to make an opening statement, shall address not only
issues it raised but also any issues raised by the responding
party. The responding party, if it chooses to make an opening
statement, also shall address all issues raised in the ADR.
Thereafter, the presentation of regular and rebuttal testimony
and documents, other evidence, and closing arguments shall
proceed in the same sequence.
(d) Except when testifying, witnesses shall be excluded from the
hearing until closing arguments. Where absolutely necessary for
the convenience of a witness, that witness may give testimony
via electronic media, provided that the testimony is not
pre-recorded.
(e) Settlement negotiations, including any statements made therein,
shall not be admissible under any circumstances. Affidavits
prepared for purposes of the ADR hearing also shall not be
admissible. As to all other matters, the neutral shall have sole
discretion regarding the admissibility of any evidence.
6. Within seven (7) days following completion of the hearing, each party may
submit to the other party and the neutral a post-hearing brief in support
of its proposed rulings and remedies, provided that such brief shall not
contain or discuss any new evidence and shall not exceed ten (10) pages.
This page limitation shall apply regardless of the number of issues
raised in the ADR proceeding.
40
7. The neutral shall rule on each disputed issue within fourteen (14) days
following completion of the hearing. Such ruling shall adopt in its
entirety the proposed ruling and remedy of one of the parties on each
disputed issue but may adopt one party's proposed rulings and remedies on
some issues and the other party's proposed rulings and remedies on other
issues. The neutral shall not issue any written opinion or otherwise
explain the basis of the ruling. The neutral shall not have the power to
award punitive damages under this Agreement. Any award of punitive
damages is expressly prohibited.
8. The neutral shall be paid a reasonable fee plus expenses. These fees and
expenses, along with the reasonable legal fees and expenses of the
prevailing party (including all expert witness fees and expenses), the
fees and expenses of a court reporter, and any expenses for a hearing
room, shall be paid as follows:
(a) If the neutral rules in favor of one party on all disputed
issues in the ADR, the losing party shall pay 100% of such fees
and expenses.
(b) If the neutral rules in favor of one party on some issues and
the other party on other issues, the neutral shall issue with
the rulings a written determination as to how such fees and
expenses shall be allocated between the parties. The neutral
shall allocate fees and expenses in a way that bears a
reasonable relationship to the outcome of the ADR, with the
party prevailing on more issues, or on issues of greater value
or gravity, recovering a relatively larger share of its legal
fees and expenses.
9. The rulings of the neutral and the allocation of fees and expenses shall
be binding, non-reviewable, and non-appealable, and may be entered as a
final judgment in any court having jurisdiction.
10. Except as provided in paragraph 9 or as required by law, the existence of
the dispute, any settlement negotiations, the ADR hearing, any
submissions (including exhibits, testimony, proposed rulings, and
briefs), and the rulings shall be deemed Confidential Information. The
neutral shall have the authority to impose sanctions for unauthorized
disclosure of Confidential Information.
41
BIOTIME, INC.
AND
▇▇▇▇▇▇ LABORATORIES
Exclusive License Agreement
Exhibit H Product Promotional Activities
1. In connection with the introduction of the Product to the medical
market place, Abbott will: (i) conduct marketing studies and consult with
Licensor in connection with the design, scope and method of conducting such
studies; and (ii) provide all technical and medical product support necessary to
commence and maintain sales and marketing of the Product. Abbott expects that
its expenditures for sales, marketing and technical and medical product support,
plus the cost of performing ▇▇▇▇▇▇'▇ obligations under clauses (i) and (iii) of
paragraph (a) of Article 7, will be not less than $6,000,000 if the marketing
studies indicate that the annual sales potential of the Product is $40,000,000
or greater.
2. Licensor intends to produce a Product package insert that will promote
the use of the Product for Normothermic Use upon data collected from the Phase
III Trial, working with the appropriate governmental regulatory agencies and
within the appropriate boundaries of safety and efficacy.
3. Licensor will analyze and compile data from the Phase III Trial for
▇▇▇▇▇▇'▇ use in preparing and producing brochures, presentations and promotional
literature encouraging appropriate utilization of the Product.
4. Licensor intends, as finances permit, to support and encourage the
presentation and publication of clinical findings at scientific and medical
conferences and in scientific and medical journals.
5. Licensor intends, as finances permit, to engage in public relations
activities such as interviews, conferences, symposia, and the preparation,
publication and distribution of written and videotaped materials for the purpose
of educating the general public about the beneficial uses of the Product.
6. To the extent that it has sufficient finances for the purpose,
Licensor will conduct pre-clinical, and after appropriate FDA approval, clinical
studies, involving other Normothermic Uses of the Product intended to expand the
markets for Normothermic Use of the Product, and involving Total Body Washout.
42